Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride

Acta Psychiatrica Scandinavica

Volumn 115, Issue 2, 2007, Pages 106-113

  Lambert, M ^a   Naber, D ^a   Eich, F X ^b   Schacht, M ^a   Linden, M ^c   Schimmelmann, B G ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Amisulpride; Atypical antipsychotics; Schizophrenia; Subjective wellbeing

Indexed keywords

AMISULPRIDE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; RATING SCALE; REGRESSION ANALYSIS; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL INTERACTION; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; WELLBEING;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SULPIRIDE;

EID: 33846274595     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2006.00862.x     Document Type: Article

References (30)

1. LAMBERT M, NABER D. Current issues in schizophrenia - overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18(suppl. 2):5-17.
2. LAMBERT M, SCHIMMELMANN BG, KAROW A, NABER D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry 2003;36(suppl. 3):181-190.
3. NABER D, KAROW A, LAMBERT M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005;111(suppl. 427):29-34.
4. MARDER SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 2005;111(suppl. 427):43-46.
5. AWAD AG, VORUGANTI LN. Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand 2005; 111(suppl. 427):6-13.
6. AWAD AG, NABER D. Neuroleptic dysphoria 50 years later. Acta Psychiatr Scand 2005;111(suppl. 427):1.
7. RITSNER M, MODAI I, ENDICOTT J et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000;61:880-889.
8. SCHIMMELMANN BG, MORITZ S, KAROW A et al. Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics. Int J Psych Clin Practice 2005;9:94-98.
9. DE HAAN L, WEISFELTM, DINGEMANS PM, LINSZEN DH, WOUTERS L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002;162:24-28.
10. KAROW A, MORITZ S, LAMBERT M, SCHODER S, NABER D. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005;38:320-326.
11. NABER D, RIEDEL M, KLIMKE A et al. Randomized double blind comparison of olanzapine and clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatrica Scand 2005;111:106-115.
12. ALPTEKIN K, AKVARDAR Y, KIVIRCIK AKDEDE BB et al. Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2005;29:239-244.
13. SIM K, MAHENDRAN R, SIRIS SG, HECKERS S, CHONG SA. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 2004;129:141-147.
14. HUPPERT JD, WEISS KA, LIM R, PRATT S, SMITH TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001;51:171-180.
15. LAMBERT M, CONUS P, EIDE P et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415-422.
16. SCHIMMELMANN B, PAULUS S, TILGNER C, SCHACHT M, SCHULTE-MARKWORT M, LAMBERT M. Side effects, subjective distress and subjective well-being in first admitted adolescents with early onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacoll 2005;15:249-258.
17. PUTZHAMMER A, PERFAHL M, PFEIFF L et al. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 2005;38:132-138.
18. SCHIMMELMANN BG, SCHACHT M, PERRO C, LAMBERT M. The initial dysphoric reaction (IDR) followed the first neuroleptic dosage. Nervenarzt 2004;75:36-43.
19. ALLISON DB, MACKELL JA, MCDONNELL DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-567.
20. BRESSAN RA, CRIPPA JA. The role of dopamine in reward and pleasure behaviour - review of data from preclinical research. Acta Psychiatr Scand 2005;111(suppl. 427):14-21.
21. PONIZOVSKY AM, GRINSHPOON A, LEVAV I, RITSNER MS. Life satisfaction and suicidal attempts among persons with schizophrenia. Compr Psychiatry 2003;44:442-447.
22. ANDREASEN NC, CARPENTER WT, KANE JM, MARDER SR, WEINBERGER DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
23. DITTMANN V, DILLING H. Chapter V (F) of ICD-10: mental, behavioural and developmental disorders - introduction and overview. Pharmacopsychiatry 1990;23(suppl. 4):137-141.
24. JANSSEN B, WEINMANN S, BERGER M et al. Guideline conformity and outcome of inpatient treatment for schizophrenia. A clinical comparison. Nervenarzt 2005;76:315-326.
25. GUY W. ECDEU assessment manual for psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976.
26. American Psychiatric Association. Diagnostic criteria from DSM-IV. Washington DC: American Psychiatric Press, 1994.
27. KAY SR, FISZBEIN A, OPLER LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261-276.
28. NABER D, MORITZ S, LAMBERT M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
29. KAROW A, MORITZ S, LAMBERT M et al. PANSS Syndromes and Quality of Life in Schizophrenia. Psychopathology 2005;38:320-326.
30. PANTELIS C, LAMBERT TJ. Managing patients with "treatment-resistant" schizophrenia. Med J Aust 2003;178(suppl. ): 62-67.